The study aim was to determine plasma lignocaine concentrations resulting from topical application of a newly formulated, sterile two-pack lignocaine gel in laparoscopic and hysteroscopic procedures. This was an open label single-centre study in which six female patients underwent laparoscopy and six underwent hysteroscopy. One venous blood sample was extracted pre-gel application, followed by 10 samples over a 24 hour period following application. Samples were centrifuged, stored at -20°C and subsequently analysed for lignocaine and its metabolite, monoethyl-glycinexylidide. Application of gel in doses between 2.7 and 5.8 mg/kg of lignocaine resulted in a maximum plasma concentration in any patient of 1520 ng/ml lignocaine and 240 ng/ml monoethyl-glycinexylidide. These maximum concentrations were recorded in a patient undergoing a laparoscopic procedure and patients undergoing hysteroscopic procedures all recorded lower maximum concentrations compared with patients undergoing laparoscopy; the maximum observed concentrations in a patient having a hysteroscopy were 420 ng/ml lignocaine and 56 ng/ml of monoethylglycinexylidide.
Lignocaine is an extensively used and wellinvestigated local anaesthetic. Its primary mechanism of action is through the blockage of voltage-gated sodium channels, which play a critical role in the generation and propagation of action potentials in neurons and muscle 1 .
Local anaesthetic has been shown to reduce postoperative pain after laparoscopy 2, 3 . It results in increased patient comfort during and after surgery because the effective duration (typically up to six hours) far outlasts the duration of most surgical interventions. Currently available lignocaine formulations are often impractical because the drug cannot always be injected directly at the site; and creams, gels and solutions cannot always be applied evenly. In addition, topical formulations are generally not sterile and their low pH can produce discomfort and reduce efficacy. A new lignocaine gel has been formulated to address these shortcomings. Pluscaine ® (Phebra Pty Ltd, Lane Cove, NSW) is a water-based, two-component lignocaine gel. Mixed prior to use, the 4.8% lignocaine gel is stable for several hours and has a near neutral pH. The gel's consistency allows easy flow into normally difficultto-reach locations and good adherence to the surgical site, resisting accidental washout.
Lignocaine's adverse effects have been well investigated 4 . At plasma concentrations above 5 µg/ml systemic toxicity may occur. Toxic plasma concentrations of lignocaine can produce serious central nervous system disturbances, including anxiety, agitation, psychosis, seizures and/or coma, and also cardiovascular toxicity, including arrhythmias and hypotension. Lignocaine is metabolised to monoethyl-glycinexylidide (MEGX), an active metabolite that can further contribute to toxicity, particularly with accumulation 5 . Even though the safe limits of lignocaine are well established, a study was undertaken, due to the unique properties of Pluscaine gel, to measure the amount of lignocaine and its primary metabolite, MEGX, present in plasma following administration of this gel during laparoscopy and hysteroscopy.
MATERIALS AND METHODS
Pluscaine is supplied in sterile twin-vial packs, one containing active lignocaine gel and the other a formulated buffer and stabiliser gel. When mixed together, the gel contains 4.8% lignocaine and is stable for several hours. The vial contents should be mixed immediately prior to application and produce a maximum volume of 7 ml of gel with the equivalent of 336 mg of lignocaine.
This study was conducted as an open, prospective single-centre trial following Good Clinical Practice/ International Conference on Harmonisation guidelines. Approval was obtained prior to commencement from the South Eastern Sydney and Illawarra Area Health Service Ethics Committee (ACTRN 12611001201965). Twelve patients were recruited between December 2009 and February 2010. The clinical phase was completed in the department of Endo-Gynaecology of the Royal Hospital for Women, Sydney, New South Wales. Subsequent plasma analysis was performed by Chemical Analysts Pty Ltd (Melbourne, Vic.). Patients were provided with information about the topical anaesthetic gel and then gave informed consent to participate. The scrub nurse mixed the gel immediately prior to use and the surgeon was then provided with a syringe containing the reconstituted buffered lignocaine. The surgeon applied the Pluscaine to the surgical field with the instrument of his/her choice. The gel was applied to the raw surface of the peritoneum and the skin incisions at laparoscopy and simply instilled into the uterine cavity at the end of the procedure at hysteroscopy. As the procedures were performed by different nurses and surgeons, it was expected that the actual amount of gel used in each procedure would not be exactly the same. Therefore all materials used to dispense, mix and administer Pluscaine were weighed pre-and post-use and this data was used to calculate the actual amount of Pluscaine applied in each procedure. No other product containing lignocaine was used during surgery. If a patient was scheduled to undergo both laparoscopy and hysteroscopy, the Pluscaine was used in one or other procedure, but not both. Vital signs were monitored both during and after the procedure. Each patient had an intravenous cannula inserted to extract the first six samples and the remaining samples were obtained by separate venepunctures. Blood samples were collected at the time of induction of anaesthesia (0 hours) and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0 and 24.0 hours (10%) after application. Blood sampling was performed according to good research practice, using appropriate equipment and technique to avoid contamination with intravenous fluids and assure proper documentation. Samples were placed in heparin vials, spun on the day of collection and stored at -20°C until all samples had been collected, after which they were sent for analysis. Serum samples were analysed for their lignocaine and MEGX content in a single batch, using liquid chromatography; tandem mass spectrometry (liquid chromatography-mass spectrometer-massspectrometer) with methodology adapted from Abdel-Rehim M et al 6 . The accuracy for lignocaine was -0.3 to 1.6% and for MEGX -6.4 to 4.0%. Precision for lignocaine was relative standard deviation 1 to 4% intra-analysis and 1.8 to 3.8% interanalysis; and for MEGX 2 to 5% for intra-analysis and 3.4 to 13% inter-analysis. Calibration standards were prepared by spiking pure lignocaine or MEGX into human plasma. The calibration range was 5 to 2200 ng/ml for lignocaine and 3 to 590 ng/ml for MEGX and the limits of quantification were 5 ng/ml for lignocaine and 3 ng/ml for MEGX.
The principal study measurements were maximum concentration (C max ) and area under the curve recorded from 0 to 24 hours (AUC 0-24h ) for both lignocaine and MEGX. Area under the timeconcentration curve from 0 to 24 hours was computed using NCSS 2007 Statistical Software (NCSS LLC, East Kaysville, Utah, USA) by linear trapezoidal integration in the following form:
where T i is the i th time value, C i is the i th concentration value, n is the number of time values, and B is the baseline value. Minor time differences between theoretical and actual sampling time had no impact on the accuracy of the results. Concentrations below the analytical level of quantification were reported as zero and zero was used in calculations. The complete data set was grouped together to determine the arithmetic mean, geometric mean, minimum, maximum, standard deviation and standard error of mean. The data set was then split into two groups -patients undergoing laparoscopic and patients undergoing hysteroscopic procedures -and each data set was subjected to the same analysis.
RESULTS
All 12 patients completed the study. Of the 132 samples extracted, one sample returned no lignocaine or MEGX despite samples either side returning significant levels of both lignocaine and MEGX. Another sample taken at 0 hours returned 440 ng/ml lignocaine and 40 ng/ml MEGX and it was suspected that these two samples had been interchanged. However extensive investigation by the research staff and the analytical laboratory concluded that this did not appear to be the case. These two samples were excluded from analysis, with all remaining 130 data points included in the analysis.
The application dose of lignocaine in this study ranged from 2.7 to 5.8 mg/kg and this resulted in a C max of plasma lignocaine between 110 and 1520 ng/ml. Figure 1 shows the time: lignocaine concentration curve, derived from the mean values of patients undergoing laparoscopic and hysteroscopic procedures. Error bars were calculated as standard error of mean (SEM where n=6). Table 1 shows the individual C max , T max (time at maximum concentration), AUC 0-24h and AUC/dose (area under the curve divided by dose) results for all patients.
DISCUSSION
Lignocaine applied topically provides an excellent local anaesthetic effect. Early systemic toxicity appears at concentrations just over 5000 ng/ml 7 .
When the CNS is affected, symptoms include blurred vision, dizziness, nausea, tremors and convulsions. Cardiac effects include cardiovascular depression that may lead to bradycardia, atrioventricular blockade and cardiac arrest. Plasma concentrations above 9000 ng/ml are associated with more severe toxicity [8] [9] [10] . This pharmacokinetic study in 12 patients found that topical application of a 4.8% lignocaine gel (dosage up to 5.8 mg/kg) resulted in a maximum plasma lignocaine level of 1520 ng/ml, which was well below that considered associated with the first signs of CNS toxicity.
There have been several studies examining plasma lignocaine levels following applications by various routes, at various body locations and from various excipients ( Table 2 ). Rousseau's publication using 2% intra-uterine gel reports a similar T max of approximately one hour after application, but a lower C max (80 ng/ml compared to 242 ng/ml using Pluscaine). The presence of lignocaine in plasma indicates that the drug is absorbed and has the potential to cause an anaesthetic effect. It could be postulated that at a higher C max , that effect will be more pronounced.
The data of this pharmacokinetic study show that C max and area under the curve plasma levels found in hysteroscopic patients were lower than those seen in laparoscopy patients. Laparoscopic application can be considered an injection into a closed system, similar to that of intramuscular or a tissue plane injection. Hysteroscopic application is an open system because the uterine cavity communicates externally through a patent cervix. Differences in C max levels between the two procedures might thus be expected. In addition, the contact surface in hysteroscopy is smaller than that potentially available at laparoscopy. In both cases however, the C max was comparable to that noted in other clinical situations in which lignocaine is effective.
CONCLUSION
This pharmacokinetic study found that application of a 4.8% lignocaine gel to patients having laparoscopy or hysteroscopy results in plasma concentrations of lignocaine below levels associated with CNS and cardiovascular complications. Plasma concentrations of lignocaine after application of Pluscaine are within a similar range to those from other clinically applied preparations.
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